
It has emerged that NICE has awarded its recommendation to Vifor Pharma’s Veltassa (patiromer) for treating hyperkalaemia, a condition classified …
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board

